Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Current Assets (2019 - 2025)

Allogene Therapeutics (ALLO) has disclosed Current Assets for 7 consecutive years, with $257.7 million as the latest value for Q4 2025.

  • Quarterly Current Assets fell 15.04% to $257.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $257.7 million through Dec 2025, down 15.04% year-over-year, with the annual reading at $257.7 million for FY2025, 15.04% down from the prior year.
  • Current Assets hit $257.7 million in Q4 2025 for Allogene Therapeutics, down from $260.7 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $716.1 million in Q1 2021 to a low of $257.7 million in Q4 2025.
  • Historically, Current Assets has averaged $442.1 million across 5 years, with a median of $470.5 million in 2021.
  • Biggest YoY gain for Current Assets was 41.96% in 2021; the steepest drop was 44.23% in 2021.
  • Year by year, Current Assets stood at $471.3 million in 2021, then rose by 12.2% to $528.8 million in 2022, then dropped by 13.18% to $459.1 million in 2023, then plummeted by 33.92% to $303.4 million in 2024, then decreased by 15.04% to $257.7 million in 2025.
  • Business Quant data shows Current Assets for ALLO at $257.7 million in Q4 2025, $260.7 million in Q3 2025, and $282.7 million in Q2 2025.